Patient Discovery

Company Overview

Patient Discovery Solutions, Inc. was founded in 2016 in Boston, Massachusetts, with a mission to integrate patient-reported life experiences into clinical decision-making [Patient Discovery, retrieved 2024]. The founding team, comprising Norm Shore (CEO), Shelby Chamberlain (CSO), and Adam Sodowick (Executive Director, Practice Solutions), built the company to address the operational and financial challenges oncology practices face in managing non-clinical patient needs [Patient Discovery, retrieved 2024]. The company's core thesis is that by systematically identifying and addressing social determinants of health (SDoH) and other barriers to care, providers can improve outcomes while unlocking new, reimbursable revenue streams.

Key operational milestones trace a path from initial concept to a focused commercial offering. After a $3.6 million seed round in late 2017, the company developed its platform [PitchBook, retrieved 2024]. A significant inflection point came in 2022 with the appointment of Sandra Fenwick, the former CEO of Boston Children's Hospital, to its board of directors [PR Newswire, 2022]. The company publicly launched its revenue cycle management solution for CMS-billable services in October 2024 [EIN Presswire, Oct 2024]. Its most recent funding event was a $2 million Series A round in April 2025 [PitchBook, retrieved 2024].

Data Accuracy: YELLOW -- Core founding and funding dates are confirmed by PitchBook and the company website; headcount figures vary across sources.

The Product and the Stack

Patient Discovery's core offering is Companion by Patient Discovery™, a software platform designed to integrate patient needs assessment and care coordination directly into the revenue cycle of oncology practices [Patient Discovery, retrieved 2024]. The product's primary function is to operationalize and monetize the identification of non-clinical barriers to care, such as transportation, food insecurity, or financial stress, which are categorized as Social Determinants of Health (SDoH) [Patient Discovery, retrieved 2024]. By embedding these workflows into the electronic medical record (EMR), the company centralizes patient needs management for clinical and non-clinical staff while generating billing-ready reports for services that qualify for CMS reimbursement, specifically Principal Illness Navigation (PIN), Community Health Integration (CHI), and SDoH risk assessment [EIN Presswire, Oct 2024].

The platform's architecture appears to be built around three interconnected modules: patient engagement, care coordination, and revenue cycle management [Patient Discovery, retrieved 2024]. A key implementation claim is that a practice can be live and producing billable claims within 90 days [Patient Discovery, retrieved 2024].

Data Accuracy: YELLOW -- Product claims are consistent across the company's website and a press release. Technical stack details are inferred from team composition and product requirements.

The Market They Are Entering

The market for oncology-focused patient management software is being reshaped by a fundamental shift in healthcare reimbursement, moving from fee-for-service to value-based models. Patient Discovery's platform targets the operationalization of SDoH screening and PIN services for cancer care, which are now reimbursable under Medicare.

Metric	Value
PIN Reimbursement per 5-MD Practice	$1,160,000 (estimated)
Medicare PIN Rate Increase (2026)	11%

The primary tailwind is regulatory: CMS's creation and expansion of reimbursement pathways for SDoH and chronic care management services transforms these activities from cost centers to revenue opportunities. Macro forces, including provider burnout and staffing shortages, increase the appeal of any solution that promises to streamline complex workflows without adding administrative burden [Patient Discovery, retrieved 2024].

Data Accuracy: YELLOW -- Market sizing is based on company-provided estimates and public CMS policy announcements. The 11% rate increase is a published regulatory fact, while the per-practice reimbursement projection is an unverified company analysis.

The Competitive Field

The competitive environment for Patient Discovery is fragmented. The company's primary competitive set consists of oncology-specific care coordination platforms, such as Thyme Care and Jasper Health, which also focus on patient navigation and support [Patient Discovery, retrieved 2024]. A second segment includes broad SDoH and social needs screening platforms like Unite Us and NowPow, which excel at community resource referral but are typically deployed across health systems generally [Patient Discovery, retrieved 2024]. The most significant adjacent substitutes are large electronic health record (EHR) vendors like Epic and Cerner, which hold the foundational patient record [Patient Discovery, retrieved 2024].

Patient Discovery's current edge is its regulatory and reimbursement specialization. The platform is explicitly built to capture CMS billing for SDoH, CHI, and PIN services, a focus sharpened by the 2024 launch of its dedicated RCM solution [EIN Presswire, Oct 2024]. This specialization is paired with a vertically integrated workflow that connects patient screening directly to billable activity tracking within the EHR [Patient Discovery, retrieved 2024].

The company's most significant exposure is its narrow focus on oncology. It does not own the primary customer relationship; the oncology practice's EHR remains the system of record. If a major EHR vendor like Epic were to develop a native PIN and SDoH workflow module and bundle it into its core offering, Patient Discovery could be disintermediated.

A plausible 18-month scenario hinges on the adoption rate of the new CMS codes. If reimbursement for PIN and SDoH services accelerates, Patient Discovery could be a winner by being the first-mover with a tuned, oncology-specific platform. Conversely, if adoption is slow, larger, better-capitalized horizontal platforms like Unite Us could be the loser in this niche, as they might deprioritize building deep oncology-specific billing features.

Data Accuracy: YELLOW -- Competitive positioning is sourced from company materials; specific competitor details and market dynamics are inferred from the product's stated focus.